China Tightens Humanoid Robot IPO Rules After Unitree Stock Drops 45%

Chinese regulators are reportedly tightening approval scrutiny for humanoid-robot startups seeking initial public offerings after Unitree Robotics’ volatile market debut. By September 9, Unitree shares had fallen to 513.51 yuan, more than 50% below their 1,100-yuan opening high; earlier reporting put the decline at roughly 45% from the post-listing peak.

The reported shift was cited by Lianhe Zaobao, relaying Reuters, on September 9. It places renewed attention on the evidence behind commercialisation claims from robot companies entering public markets, particularly after Unitree’s own IPO-review materials showed that research and education accounted for most of its humanoid-robot revenue.

Unitree’s STAR Market debut

Unitree listed on Shanghai’s STAR Market on August 19 at an IPO price of 150.80 yuan per share. The stock opened at 1,100 yuan, a 629% jump, before ending its first trading day at 845 yuan, still up 460% from the offer price, according to the South China Morning Post.

The figures describe different points of the decline: the 45% figure cited in earlier coverage was a pullback from the post-listing peak, while the stock’s 513.51-yuan price on September 9 was more than 50% below the 1,100-yuan debut high and well below both its opening level and first-day closing price.

That sequence compressed a large reassessment into a short period. Investors initially assigned a sharply higher price to the company than the IPO offered, then marked down the shares substantially before the reported change in regulatory posture emerged.

Reported IPO scrutiny follows volatility

The September 9 report said Chinese regulators were increasing approval scrutiny for humanoid-robot startups pursuing IPOs, following Unitree’s volatile debut. The report does not turn the market decline into an official explanation for the scrutiny, but it connects the regulatory development to the company’s listing as the immediate backdrop.

For prospective issuers, the focus is consequential because a public offering asks investors to assess both a young technology market and the durability of a company’s revenue base. Unitree’s pre-listing exchange review provides a more specific record of the issues that had already been examined in one prominent case.

The scrutiny is reported, rather than set out in the research as a published new rule or a quantified approval standard. Its significance is therefore clearest as a shift in the attention facing humanoid-robot IPO candidates, not as a stated change to a particular listing threshold.

Research and education drove humanoid revenue

Shanghai Stock Exchange IPO-review materials showed that 73.60% of Unitree’s humanoid-robot revenue in January to September 2025 came from research and education, while industry applications accounted for 9.01%, according to the exchange’s March 20 review materials. Unitree’s reported humanoid-robot sales were therefore concentrated in research and education rather than industrial deployment during the period reviewed. The figures describe the company’s reported revenue mix for that period and do not measure the entire addressable market for humanoid robots or determine how future sales will develop.

The Shanghai Stock Exchange also questioned Unitree about commercial use cases, technology, suppliers and large-model development.

A 61 billion yuan initial valuation

Unitree raised about 6.1 billion yuan in its IPO by selling 40.45 million shares. The shares represented 10% of its enlarged share capital, implying an initial market capitalisation of about 61 billion yuan.

As Unitree moved into public trading, the scale of its valuation made its operating disclosures more important. The company’s debut showed investors were willing to price it far above its offer price at the open; the later pullback and its disclosed revenue concentration, however, underline why commercial-use evidence is likely to remain central for humanoid-robot issuers seeking the market.

Disclaimer: This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.